NF-kappaB Signaling
Phospho-NF-κB p65 (Ser276) Blocking Peptide
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1437S | 100 μg | 16,000 | |
|
NFkB-p65抗体製品一覧
| 使用目的 | |
| Phospho-NF-κB p65 (Ser276) Antibody (#3037) の反応をブロックし、抗体の反応特異性を確認するために使用 |
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using Phospho-NF-κB p65 (Ser276) Antibody #3037 in the presence of control peptide (left) or Phospho-NF-κB p65 (Ser276) Blocking Peptide (right).
Transcription factors of the nuclear factor κ B (NF-κB)/Rel family play a pivotal role in inflammatory and immune responses (1,2). There are five family members in mammals: RelA, c-Rel, RelB, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). Both p105 and p100 are proteolytically processed by the proteasome to produce p50 and p52, respectively. Rel proteins bind p50 and p52 to form dimeric complexes that bind DNA and regulate transcription. In unstimulated cells, NF-κB is sequestered in the cytoplasm by IκB inhibitory proteins (3-5). NF-κB-activating agents can induce the phosphorylation of IκB proteins, targeting them for rapid degradation through the ubiquitin-proteasome pathway and releasing NF-κB to enter the nucleus where it regulates gene expression (6-8). NIK and IKKα (IKK1) regulate the phosphorylation and processing of NF-κB2 (p100) to produce p52, which is then translocated to the nucleus (9-11).
-
Baeuerle, P.A. and Henkel, T. (1994) Annu Rev Immunol 12, 141-79.
-
Baeuerle, P.A. and Baltimore, D. (1996) Cell 87, 13-20.
-
Haskill, S. et al. (1991) Cell 65, 1281-9.
-
Thompson, J.E. et al. (1995) Cell 80, 573-82.
-
Whiteside, S.T. et al. (1997) EMBO J 16, 1413-26.
-
Traenckner, E.B. et al. (1995) EMBO J 14, 2876-83.
-
Scherer, D.C. et al. (1995) Proc Natl Acad Sci USA 92, 11259-63.
-
Chen, Z.J. et al. (1996) Cell 84, 853-62.
-
Senftleben, U. et al. (2001) Science 293, 1495-9.
-
Coope, H.J. et al. (2002) EMBO J 21, 5375-85.
-
Xiao, G. et al. (2001) Mol Cell 7, 401-9.